Document is current
Any future updates will be listed below
-
Authors
Wang, Jiawan
Sarkar, Arnab
Garcia, Natalia
Zhang, Lindy
Calizo, Ana
Lisok, Alla
Campos, Katia
He, Funan
Punjaala, Nishanth
Marple, Teresa
Pollard, Kai
Zheng, Siyuan
Lucas, Calixto-Hope G.
Cooke, Vesselina G.
Pratilas, Christine A.
Vaseva, Angelina V.
- License Information
-
More Information
Article History
Received: 2 May 2025
Accepted: 15 August 2025
First Online: 29 September 2025
Declarations
:
: All mouse experiments were approved by the Institutional Animal Care and Use Committee (IACUC) at Johns Hopkins (JH) and University of Texas at San Antonio. The approval of all experiments using patient-derived cell lines and xenografts was waived and such research use was covered in their respective original IRB protocols with written informed consent from participants.
: All authors reviewed the manuscript and consented to its publication.
: Vesselina G. Cooke is an employee and stockholder of Novartis BioMedical Research (NBR). NBR provided LXH254/ naporafenib and trametinib for testing in preclinical models under material transfer agreements to Johns Hopkins University (JHU) and UT Health San Antonio (UTHSCSA). JW and CAP have a pending patent (#US20240238284A1); CAP has an active patent (#US7812143B2), neither related to this study. AVV and VGC have a pending patent (#US20230321110A1), combination therapy of a RAF inhibitor and a MEK inhibitor for the treatment of sarcoma. The other authors have no additional conflicts of interest.
